AHFS Drug Information 2025

With expanded and revised content, AHFS^® DI™ helps you protect your patients and your practice. It is federally recognized as an official compendium for establishing drug use standards, the only compendium published by a professional and scientific society, and the drug information reference trusted by pharmacists and other healthcare professionals for over 60 years.

Updates in this edition include*:

• Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
• Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
• Contemporary topics such as vaccines and treatments for mPox disease, new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more 
• Pharmacogenomic considerations in drug dosing and selection
• Expanded content on new and emerging gene therapies 
• New content on over 200 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 265 medications
• Oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee

*both print and electronic versions

Published under the Editorial Authority of ASHP^®
American Society of Health-System Pharmacists^®

EDITORIAL STAFF
Senior Vice President, Professional Development and Publishing: Daniel J. Cobaugh, PharmD, DABAT, FAACT

AHFS Editor-in-Chief and Senior Editorial Director: Michael Gabay, PharmD, JD, BCPS, FCCP

Deputy Editor-in-Chief: Shingyee Cindy Huang, PharmD 

Principal Editorial Contributors: The University of Illinois at Chicago Drug Information Group

Editorial Contributors: Nicole Acquisto, PharmD, FASHP, FCCM, FCCP, BCCCP; Linda Bedford Arcuri, PharmD; Heather Draper, PharmD, BCPS, BCEMP; Justyna Fydrych, PharmD; Micheline Goldwire PharmD, MS, MA; Donna Lisi, PharmD; Natalie A. Mendham, PharmD; Cambrey Bao-Phuong Nguyen, PharmD; Kelly Pillinger, PharmD, BCPS, BCIDP; Tonya Scardina, PharmD, BCIDP; Margaret Segovia, PharmD; Elaine K. Snow, BS Pharm; Stephanie Weightman, PharmD, BCPS, BCPPS, BCEMP; Karen M. Whalen, BS Pharm, BCPS, FASHP; and Barbara F. Young, PharmD, MHA.

Contributors: Auburn University Drug Information Service; Belmont University Drug Information Service; Creighton University Drug Information Service; Medical University of South Carolina Drug Information Service; the University of Arizona Drug Information Service; the University of Missouri, Kansas City Drug Information Service; and the University of Rhode Island Drug Information Service

Assistant Editor for Injectable Drug Information: Natalie C. Rosanelli, PharmD 

Clinical Informatics Analyst: Kevin Son, PharmD, MHI 

Editorial Coordinator: Alexandra Rallo, BA

Content Management and Publishing Specialist: Shawna Rafalko, BA

Director of Production and Platform Services: Johnna Hershey, BA

Consultant: Elizabeth Shannon, BA

FORMER EDITORS
Charles B. Cleveland
Donald E. Francke
William M. Heller
Judith A. Kepler
George P. Provost
Mary Jo Reilly
Gerald K. McEvoy
Elaine K. Snow

AHFS ONCOLOGY EXPERT COMMITTEE
Chase Ayres, PharmD, BCOP
Jason Bergsbaken, PharmD, MBS, BCOP
Rachel Bubik, PharmD, BCOP, BCPS
Caroline Clark, MSN, APRN, OCN, AG-CNS
Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP
Christine Gegeckas, RPh, BCOP
Chelsea Gustafson*, PharmD, BCOP
Kirollos Hanna, PharmD, BCPS, BCOP
Tara Higgins*, PharmD, BCPS, LECOM
Isabel Houlzet*, PharmD, BCPS, BCOP
Andrew (Weiyi) Li, PharmD
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Eve Segal, PharmD, BCOP
Kate Taucher, PharmD, MHS, BCOP, FASHP, FAPO
John Villano, MD, PhD
Kathleen Wiley, MSN, RN, AOCNS

* Appointed in cooperation with the Hematology/Oncology Pharmacy Association (HOPA)

“What sets AHFS DI apart from the [other drug information books available] is its comparative, unbiased, evaluative drug information and its continually maintained relevance.”

Patrick J. Scoble, PharmD, Doody’s Review Service

“Using an independent, evidence-based evaluative process, the drug monographs incorporate information from pertinent references in the literature and expert therapeutic guidelines. This point-by-point analysis and evaluation of the literature makes this reference comprehensive, evaluative, and unbiased.”

Yen Deng, PharmD